Cisco DNA vs Meraki Licensing: Two Subscription Models

Cisco DNA licensing and Meraki licensing are both subscription-funded, but they license two different things. DNA is the Catalyst Center software subscription — Essentials, Advantage, and Premier tiers, billed per device per year — that layers automation, assurance, and analytics on top of Catalyst hardware, which itself carries a separate, perpetual Network Essentials or Network Advantage license underneath. Meraki licensing is a single, mandatory, all-in-one cloud subscription bound to each device: there's no separate perpetual layer beneath it, the subscription is the license, and the device stops forwarding traffic if it lapses. Choosing between them is really choosing a control-plane model — on-prem/hybrid Catalyst Center versus full cloud dashboard — and the licensing mechanics follow from that choice.

At a glance

Both models are recurring, term-based subscriptions, but what each one licenses and what happens when it lapses differ meaningfully. Confirm exact tier contents and current lapse behavior for your specific hardware in a validated quote, since Cisco periodically adjusts both programs.

What Cisco DNA licensing actually licenses

DNA licensing — sold in Essentials, Advantage, and Premier tiers, the same names used for the perpetual Network license, which is a genuinely confusing overlap worth flagging separately — is the subscription layer that runs Catalyst Center: automation, assurance and analytics, and the higher-order policy and segmentation features that turn a collection of switches into a managed, self-reporting network. It's billed per device, per year, on the term you choose, and it sits on top of Catalyst switching, routing, and wireless hardware that already carries its own perpetual network-stack license.

That's the detail buyers most often miss: DNA licensing doesn't replace or include the hardware's baseline license. A Catalyst switch needs its perpetual Network Essentials or Advantage license regardless of whether a DNA subscription is attached, and the DNA subscription tier generally can't exceed the perpetual tier underneath it. DNA is what you buy to get Catalyst Center's automation and assurance; the perpetual license is what makes the switch itself work.

What Meraki licensing actually licenses

Meraki collapses that two-layer structure into one. There's no separate perpetual license underneath a Meraki device — the per-device cloud subscription is the entire license, and it covers feature entitlement, cloud dashboard management, and Cisco support in a single line item. Every access point, switch, and appliance needs an active license to stay on the dashboard and keep forwarding traffic; there's no baseline hardware-only mode to fall back on the way there is with Catalyst.

That design has a real consequence worth planning around: a lapsed Meraki license doesn't just lose you automation features, the way a lapsed DNA subscription does on a Catalyst switch. It stops the device from passing traffic. Budgeting Meraki renewals with real urgency, not treating them as a soft deadline, is a direct result of how the license is architected.

The control-plane question underneath the licensing

The licensing structures follow from a deeper architectural choice, so it's worth naming it briefly rather than treating the two as interchangeable subscriptions with different price tags. DNA licensing runs Catalyst Center, which can operate on-premises or in a private cloud you control — the management plane stays inside your boundary. Meraki licensing runs Cisco's cloud dashboard, full stop; there's no on-prem control-plane option. If your environment has a hard requirement to keep management on-premises, that constraint answers the licensing question before cost enters the conversation at all.

For everyone else, the practical question is which operating model fits: do you want to own and operate a controller in exchange for on-prem control and deeper tuning, or hand that operational layer to Cisco's cloud in exchange for zero-touch deployment and a lighter local footprint. Cost comparisons between DNA and Meraki only mean much once that operating-model question is answered, since you're pricing two different ownership structures, not two versions of the same thing.

What happens when each subscription lapses

This is the practical difference that matters most for planning renewals. When a DNA subscription lapses on a Catalyst switch, the automation and assurance features tied to Catalyst Center stop working, but the switch generally keeps forwarding traffic on its perpetual Network Essentials or Advantage license underneath — you lose visibility and automation, not connectivity. When a Meraki license lapses, there's no perpetual layer to fall back on, and the device stops forwarding traffic. Both are real problems, but they are not the same severity of problem, and renewal planning should treat them differently.

In practice this means Meraki renewals deserve a harder deadline and less tolerance for delay than DNA renewals, purely because of what's at stake when the clock runs out. Neither should be left to lapse, but if you're triaging which renewal to chase first when time is short, the one that stops traffic outright is the more urgent one.

Which should you choose?

• Already invested in Catalyst hardware, and management needs to stay on-premises or in a private cloud: DNA licensing on Catalyst Center is the natural fit.
• Distributed multi-site organization that wants zero-touch deployment and no controller to operate: Meraki's all-in-one cloud subscription does that job directly.
• Regulated or air-gapped environment with a hard requirement against cloud-managed control planes: DNA/Catalyst Center is the only one of the two that satisfies it.
• Lean central IT team supporting many small, similar sites: Meraki's bundled licensing and cloud dashboard reduce the operational load per site.
• Mixed estate — a flagship campus on Catalyst, distributed branches on Meraki: budget both subscription models separately rather than forcing one architecture everywhere.